AZTAAzenta, Inc.
Is the business good?
Margins compressing. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Operating margin has narrowed over the past few years, profitability per dollar of sales is eroding.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is AZTA?
Azenta, Inc. earns −12% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
Return on invested capital · cost of capital 9.0% · 21 points below what the capital costs: growth destroys value
- Operating margin
- −29%
Operating margin · Medical Instruments & Supplies median 6.6% · 12 months to Q3 2026
- Share count, year on year
- −1.1%
Share count, year on year · bought back, each share owns more of the company
- R&D as % of revenue
- 5.8%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −9.4% |
| FY2021 | −6.0% |
| FY2022 | −4.5% |
| FY2023 | −11% |
| FY2024 | −8.9% |
| FY2025 | −4.5% |
Details›
- Gross margin12 months to Q3 2026
- 44%
- Operating margin12 months to Q3 2026
- −29%
- Net margin12 months to Q3 2026
- −20%
- Free cash flow margin
- 1.6%
- R&D as % of revenue
- 5.8%
- Revenue, trailing twelve months
- $614M
- Free cash flow, trailing twelve months
- $9.9M
- Net income, trailing twelve months
- −$123M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- −12%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Medical Instruments & Supplies
Ranks #15 of 21 by RyuScore